The GLP-1 weight loss market in 2026 features diverse programsfrom telehealth startups to established pharmacy networksbut clinical outcomes depend on individual metabolic factors, not rankings
Exclusive-Cigna drops coverage of GLP-1 obesity drugs for its own employees By Amina Niasse NEW YORK, June 2 (Reuters) - Health insurer Cigna will stop covering GLP-1 weight-loss drugs including Novo Nordisk's Wegovy and Eli Lilly's Zepbound in its employee health plan effective July 1, according to materials viewed by Reuters on Tuesday
Standardized manufacturing and independent verification with respect to purity, potency, sterility, and stability
These injections can be an effective way to replenish your bodys vitamin B12 levels if you have a deficiency
Biomarker analyses reveal systematic endocrine disruption, characterized by 28.5% testosterone suppression and 45.2% FSH elevation in exposed populations, indicating primary testicular dysfunction rather than hypothalamic-pituitary axis impairment
A sensitivity analysis after removal of these two studies showed homogeneity between the remaining studies but the meta-analysis still showed no significant effects of carnitines on sperm concentration (MD 0.79, 95% CI 0.39 to 1.96
